Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
Incyte (Nasdaq:INCY) today announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process.
“While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group Vice President, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent U.S. Food & Drug Administration acceptance of our Biologics License Application for Priority Review – brings us closer to providing a new option for patients in Europe with this rarely studied tumor.”
The MAA is based on data from the Phase 2 POD1UM-202 trial evaluating retifanlimab in previously treated patients with locally advanced or metastatic SCAC who have progressed on, or are intolerant of, standard platinum-based chemotherapy which were presented at the 2020 virtual ESMO Congress.
SCAC is associated with human papillomavirus (HPV) and HIV infections and accounts for almost 3% of digestive system cancers.1 In Europe, each year approximately 12,000 patients receive SCAC diagnosis.2 Patients with metastatic SCAC have a poor 5-year survival and there are no approved treatments for patients who progress on platinum therapy.3
About POD1UM-202
POD1UM-202 (NCT03597295) is a global, open-label, single-arm, multicenter, Phase 2 study evaluating retifanlimab in patients with squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. Retifanlimab 500 mg is administered intravenously every 4 weeks.
The primary endpoint is objective response rate (ORR) as determined by independent central review using RECIST v1.1. Secondary endpoints include additional measures of clinical benefit ‒ duration of response (DOR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS); safety and pharmacokinetics.
For more information about the study, please visit https://clinicaltrials.gov/ct2/show/NCT03597295.
About POD1UM
The POD1UM (PD1 Inhibitor Clinical Program in Multiple Malignancies) clinical trial program for retifanlimab includes POD1UM-202, POD1UM-303 in SCAC along with and benchmarking studies in endometrial cancer, Merkel cell carcinoma and other solid tumors. A Phase 3 trial in NSCLC (POD1UM-304) is also enrolling, as are studies in combination with epacadostat, pemigatinib, and other development compounds in the Incyte portfolio.
About Retifanlimab
Retifanlimab (formerly INCMGA0012), an investigational intravenous anti-PD1 antibody, is currently under evaluation in registration-directed trials as a monotherapy for patients with microsatellite instability-high endometrial cancer, Merkel cell carcinoma and squamous cell anal carcinoma (SCAC); and in combination with platinum-based chemotherapy for patients with non-small cell lung cancer.
Retifanlimab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of anal cancer, and the Biologics License Application for retifanlimab has been accepted for Priority Review.
In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab. In 2019, Incyte and Zai Lab announced a collaboration and license agreement for the development and commercialization of retifanlimab in Greater China.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements about whether or when the EMA may authorize retifanlimab for the treatment of patients with squamous cell anal carcinoma (SCAC), the potential of retifanlimab to provide a meaningful treatment for patients with SCAC, the retifanlimab development program, and the safety and efficacy of retifanlimab in patients with SCAC, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by European regulatory authorities or other regulatory authorities, including the U.S. FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ending December 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.
1 Ghosn M, et.al. Anal cancer treatment: current status and future perspectives. World J Gastroenterol 2015;21:2294-2302.
2 Globocan
3 Glynne-Jones R, et al. Ann Oncol. 2014;25(suppl 3):iii10–iii20.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005125/en/
Contact information
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Ela Zawislak
+41 21 343 3113
ezawislak@incyte.com
Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mohammed bin Rashid Al Maktoum Global Water Award extends application deadline until end of May7.5.2024 20:01:00 CEST | Press release
The UAE Water Aid Foundation (Suqia UAE), under the umbrella of the Mohammed bin Rashid Al Maktoum Global Initiatives, has extended application deadline for the 4th cycle of the Mohammed bin Rashid Al Maktoum Global Water Award, with total prizes of USD 1 million. The award aims to find sustainable and innovative solutions to address water scarcity worldwide. Companies, research and development centres, research institutes, innovators, and youth can submit their applications until 31 May 2024. This encourages the development of innovative projects, technologies, and prototypes in water desalination and purification using renewable energy sources, including solar, wind, biomass, hydropower, osmotic power, and geothermal technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507709620/en/ Mohammed bin Rashid Al Maktoum Global Water Award extends application deadline until end of May (Graphic: AETOSWire) This award ref
Fields and the Sun: Agricultural PV, an Opportunity for the Energy and the Farming Industry7.5.2024 17:53:00 CEST | Press release
The EU’s objectives are ambitious: The total solar energy deployment is to reach around 750 gigawatts by 2030. In this context, dual land use concepts, especially agricultural PV, are gaining importance. At Intersolar Europe, the world’s leading exhibition for the solar industry, visitors will have the opportunity to see a varied range of technologies, products and solutions for agricultural PV, and to gain deeper insights into best practices and the latest developments. Intersolar Europe will take place from June 19–21, 2024 as part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry, in Munich. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507054567/en/ Latest tracking systems for agricultural PV applications will be presented at the "Intersolar Europe Special Exhibit Agrivoltaics". (© BayWa r.e.) Agriculture or renewable sources of energy – in the past, it was either, or. A
Verimatrix XTD Enterprise Suite Triumphs at 2024 Cybersecurity Excellence Awards7.5.2024 17:45:00 CEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that its Verimatrix XTD Enterprise Suite won a prestigious 2024 Cybersecurity Excellence Award. This year’s accolade stands as the most recent honor in a multi-year series of award wins recognizing Verimatrix XTD as the trusted, enterprise-grade mobile application security solution of choice. The Verimatrix XTD Enterprise Suite has become the go-to cybersecurity solution for enterprises intent on shielding their iOS and Android applications from reverse engineering and other cyber attacks. Setting itself apart from the competition, Verimatrix offers versatile deployment options, including on-premises toolkits, zero-code cloud solutions, and a bespoke white glove service that ensures cybersecurity defenses are swiftly and cost-effectively implemented into DevSecOps workflows and continuous integration and continuous deployment (
Energy Vault Announces Successful Testing and Commissioning of First EVx 100 MWh Gravity Energy Storage System by China Tianying, Extension of Atlas Renewable Licensing Agreement to 15 Years7.5.2024 15:58:00 CEST | Press release
Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a leader in sustainable, grid-scale energy storage solutions, today announced the successful testing and commissioning of the Rudong EVx™ gravity energy storage system (GESS) by China Tianying Co., Ltd (CNTY). Testing included the successful charging and discharging of units of the 25 MW/100 MWh GESS invested in and built by CNTY in partnership with Energy Vault and Atlas Renewable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507725790/en/ The first set of charging and discharging units of the Rudong 100MWh gravity energy storage project was successfully tested. (Photo: Business Wire) In addition to the successful testing of the Rudong EVx, Energy Vault announced the extension of its EVx licensing agreement with Atlas Renewable from 7.5 to 15 years, reflecting the key role that gravity storage technology stands to play in China’s energy transition and achieving
Landmark Report Proves That High Nicotine Use Does Not Lead to High Rates of Health Issues7.5.2024 15:53:00 CEST | Press release
A new report released today in Stockholm by international health experts, "No Smoke, Less Harm" presents compelling evidence that despite similar levels of nicotine consumption, Sweden boasts significantly lower rates of tobacco-related diseases compared with other European nations. The report, which was unveiled during an event organised by Smoke Free Sweden, a global health advocacy group, details rates of nicotine usage in Sweden and a number of comparable countries, finding that nicotine use was not a factor in tobacco-related disease. Furthermore, the report provided further evidence that what does affect consumers’ health is the method of consumption. While using alternative products such as snus did not pose a significant risk, smoking is linked with a high incidence of death and disease. While nicotine consumption in Sweden mirrors the European average, the country reports a 41% lower incidence of lung cancer and fewer than half the tobacco-related deaths of its European peers.